The Heart Failure Patient Who Is 'Just Depressed'

This is a medical emergency, not an antidepressant question. The picture is delirium from digoxin toxicity: drowsiness, nausea, ataxia, confusion, and xanthopsia (yellow-tinged vision) in a patient with a level of 1.9 ng/mL and a creatinine that has risen from 1.3 to 1.7. Amiodarone inhibits P-glycoprotein and reduces digoxin clearance; sertraline is a weak P-glycoprotein inhibitor as well; worsening renal function does the rest. Older age and low body weight lower the toxic threshold.

Immediate actions: hold digoxin, obtain a 12-lead ECG looking for bradyarrhythmia or block, recheck the level, potassium (4.8 - watch for hyperkalemia), magnesium, and renal function. If there is a life-threatening arrhythmia, digoxin-specific antibody fragments are the treatment.

Do not stop there. Sodium 128 from an SSRI, heart failure, and loop diuretics is a second driver of confusion and must be corrected slowly. INR 3.8 reflects amiodarone's inhibition of warfarin metabolism compounded by acute illness and mild CYP2C9 inhibition from sertraline - the anticoagulation service needs to know today.

Answer the question asked, but in the right order. Her three-month history of anhedonia, early waking, and weight loss may well represent major depression that predates this admission. But you cannot diagnose depression through delirium, and a PHQ-9 administered now is invalid. Delay the antidepressant decision until the delirium clears; today, correct the toxicity and reassess. Note also that grief and depression overlap - 15 pounds, early waking, and anhedonia beyond two months favors major depression - and that depression in heart failure predicts readmission and mortality, so this is not a problem to shelve indefinitely.

Sertraline is already a defensible choice in heart failure: minimal anticholinergic burden, little orthostatic effect, modest QT prolongation, and a large safety experience in cardiac patients. If she has had an adequate trial at 100 mg for six months with no response, increasing to 150 mg is reasonable - but tomorrow or next week, after the delirium resolves and with a baseline ECG, not today.

What to avoid and why:

• Citalopram above 20 mg and escitalopram above 10 mg in this patient: dose-dependent QT prolongation additive to amiodarone.
• Fluoxetine and paroxetine: potent CYP2D6 inhibition raises carvedilol levels (bradycardia, hypotension) and paroxetine adds anticholinergic burden; fluoxetine's long half-life complicates any change.
• Tricyclics: orthostasis, conduction effects, anticholinergic delirium.
• Bupropion: activating, raises blood pressure, avoid in arrhythmia.

Mirtazapine is a reasonable second-line option if appetite and insomnia dominate - 7.5–15 mg at night - but counsel about edema and weight gain, which can be poorly tolerated in heart failure.

Monitoring specific to her:

• Sodium at 1–2 weeks after any serotonergic change; SSRIs plus heart failure plus diuretics is a high-risk combination for hyponatremia.
• INR within 3–5 days of a sertraline change; sertraline mildly inhibits CYP2C9 and SSRIs increase bleeding risk, which is relevant on warfarin.
• ECG for QTc before and after any dose increase.
• Renal function, since accumulating metabolites affect several of her drugs.

Nonpharmacologic treatment is not optional here: behavioral activation, CBT adapted for cardiac illness, cardiac rehabilitation, sleep hygiene, and advance care planning.

Write a note structured as question asked / findings / answer / plan, because the consult question was 'increase the sertraline?' and the clinically correct answer is 'not today, and here is why.'

Orders and monitoring:

• Hold digoxin; recheck level and ECG in 24 hours; correct potassium and magnesium.
• Sodium recheck daily while inpatient and at 1–2 weeks after any antidepressant change.
• INR today and in 3 days; notify the anticoagulation service of the amiodarone-warfarin-sertraline interaction.
• Baseline ECG with QTc; repeat after any psychotropic change.
• Continue sertraline 100 mg for now; reassess in 48 hours once the delirium has cleared. Do not make two medication changes in the same 24 hours.
• Explicit 'avoid' list in the chart: citalopram above 20 mg, fluoxetine, paroxetine, tricyclics, NSAIDs, decongestants.

Communication: call the primary team rather than relying on the note alone; ask pharmacy for a formal interaction review, which will be high-yield with eight cardiac medications; request cardiology input on the digoxin and amiodarone. Tell nursing what to watch for - sedation, confusion, visual change, falling sodium.

Reframe the larger question. Her heart failure carries a poor prognosis, and depression treatment is about quality of life, not adherence metrics. Once she is lucid, screen for suicidal ideation and hopelessness explicitly, ask what matters to her, and involve palliative care if her goals are unclear. Reassess mood with a validated measure only when she is no longer delirious, and only then decide whether the sertraline dose should change.